Nature Communications (Nov 2020)
ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL
- Silvia Pietrobono,
- Giulia Anichini,
- Cesare Sala,
- Fabrizio Manetti,
- Luciana L. Almada,
- Sara Pepe,
- Ryan M. Carr,
- Brooke D. Paradise,
- Jann N. Sarkaria,
- Jaime I. Davila,
- Lorenzo Tofani,
- Ilaria Battisti,
- Giorgio Arrigoni,
- Li Ying,
- Cheng Zhang,
- Hu Li,
- Alexander Meves,
- Martin E. Fernandez-Zapico,
- Barbara Stecca
Affiliations
- Silvia Pietrobono
- Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO)
- Giulia Anichini
- Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO)
- Cesare Sala
- Department of Clinical and Experimental Medicine, University of Florence
- Fabrizio Manetti
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena
- Luciana L. Almada
- Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic
- Sara Pepe
- Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO)
- Ryan M. Carr
- Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic
- Brooke D. Paradise
- Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic
- Jann N. Sarkaria
- Department of Radiation Oncology, Mayo Clinic
- Jaime I. Davila
- Department of Health Sciences Research, Mayo Clinic, Rochester
- Lorenzo Tofani
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence
- Ilaria Battisti
- Proteomics Center, University of Padova and Azienda Ospedaliera di Padova
- Giorgio Arrigoni
- Proteomics Center, University of Padova and Azienda Ospedaliera di Padova
- Li Ying
- Department of Dermatology, Mayo Clinic
- Cheng Zhang
- Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic
- Hu Li
- Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic
- Alexander Meves
- Department of Dermatology, Mayo Clinic
- Martin E. Fernandez-Zapico
- Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic
- Barbara Stecca
- Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO)
- DOI
- https://doi.org/10.1038/s41467-020-19575-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
Understanding the molecular events controlling melanoma progression are necessary to find improved therapeutics. Here, the authors report oncogenic SOX2-GLI1 transcriptional complex to drive melanoma invasion through the induction of the sialyltransferase ST3GAL1, and report ST3GAL1-AXL axis as driver of melanoma metastasis.
